OncoMatch/Clinical Trials/NCT05664464

Glutamate Inhibitors in Glioblastoma

Is NCT05664464 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Gabapentin and Sulfasalazine for glioblastoma.

Phase 1/2RecruitingUniversity of ZurichNCT05664464Data as of May 2026

Treatment: Gabapentin · Sulfasalazine · Memantine · Temozolomide — The goal of this 1:1 randomized, multi-center, open-label phase Ib/II clinical trial is to explore the efficacy of the add-on of the anti-glutamatergic drugs gabapentin, sulfasalazine and memantine to standard chemoradiotherapy with temozolomide compared to chemoradiotherapy alone in patients with newly diagnosed glioblastoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Prior therapy

No prior treatment (treatment-naive required)

Cannot have received: radiotherapy of the brain

Any prior radiotherapy of the brain or radiotherapy with potential overlap of the irradiation fields

Cannot have received: investigational drug

Participation in another study with investigational drug within the 30 days preceding and during the present study

Lab requirements

Blood counts

adequate haematological function

Kidney function

adequate renal function

Liver function

adequate liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify